Pfizer and Genentech Duke it Out in Court over Herceptin Biosimilar Patents Post author:Sam Post published:November 21, 2017 Post category:BioPharma Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Source: BioSpace You Might Also Like Boston's PureTech Gives Birth to New Biotech and Its Name is April 11, 2017 Alexion is Under Investigation by the Office of Inspector General July 6, 2017 Blue Earth Diagnostics Receives Positive Opinion For Axumin (Fluciclovine (18F)) For PET Imaging Of Recurrent Prostate Cancer March 23, 2017
Blue Earth Diagnostics Receives Positive Opinion For Axumin (Fluciclovine (18F)) For PET Imaging Of Recurrent Prostate Cancer March 23, 2017
